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Essentials: 
• C. canimorsus causes severe dog bite related blood stream infections. 
• We investigated if C. canimorsus contributes to bleeding abnormalities during infection. 
• The C. canimorsus protease CcDPP7 causes factor X dysfunction by N-terminal 
cleavage. 
• CcDPP7 inhibits coagulation in vivo, which could promote immune evasion and trigger 
hemorrhage. 
 
Abstract 
Background: Capnocytophaga canimorsus is a Gram-negative bacterium, which belongs to 
the oral flora of dogs and causes fulminant sepsis in humans who have been bitten, licked or 
scratched. In patients, bleeding abnormalities, such as petechiae, purpura fulminans or 
disseminated intravascular coagulation (DIC) occur frequently.  
Objective: We investigated whether C. canimorsus could actively contribute to these 
bleeding abnormalities. 
Methods: Calibrated automated thrombogram and clotting time assays were performed to 
assess the anticoagulant activity of C. canimorsus 5 (Cc5), a strain isolated from a fatal 
human infection. Clotting factor activities were measured with factor deficient plasma. Factor 
X (FX) cleavage was monitored using the radiolabeled zymogen and western blot. 
Mutagenesis of Cc5 genes encoding putative serine proteases was performed to identify the 
protease cleaving FX. Protein purification was done by affinity chromatography. Edman-
degradation allowed detection of N-terminal cleavage of FX. Tail bleeding times were 
measured in mice. 
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Results: We found that Cc5 inhibited thrombin generation and increased the prothrombin 
time (PT) and the activated partial thromboplastin time (aPTT) of human plasma via FX 
cleavage. A mutant, unable to synthesize a type 7 dipeptidyl peptidase (DPP7) of the S46 
serine protease family, failed to proteolyse FX. The purified protease (CcDPP7) cleaved FX 
heavy and light chains from the N-terminus and was active in vivo after i.v. injection.  
Conclusions: This is to our knowledge the first study demonstrating a detailed mechanism 
for FX inactivation by a bacterial protease and it is the first functional study associating 
DPP7 proteases with a potentially pathogenic outcome. 
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Introduction 
Capnocytophaga canimorsus is a Gram-negative bacterium belonging to the family of 
Flavobacteriaceae in the Bacteroidetes phylum [1]. It is part of the oral flora of dogs [1, 2] 
and causes rare but severe dog bite related blood stream infections in humans with a 
mortality as high as 30% [3] (for reviews see [3-5]). C. canimorsus sepsis can be 
accompanied by bleeding disorders, such as disseminated intravascular coagulation (DIC) 
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(13-35 %*), that often results in gangrene (8-13%*). Patients frequently show skin 
manifestations, including petechiae and purpura (11-46%*) [3-6]. Furthermore, one third of 
autopsies, performed on deceased individuals, revealed hemorrhage of adrenal glands [3].  
 
The presence of pathogens or their products in circulation provokes several pro-coagulant 
processes, such as tissue factor (TF) expression by monocytes and endothelial cells, 
fostering entrapment of bacteria inside fibrin clots [7]. The importance of coagulation in 
innate immunity is illustrated by in vivo data. For instance, infection of fibrin deficient or 
coumadin treated mice with Yersinia enterocolitica leads to an elevated pathogen burden 
and reduced survival [8]. Some bacteria interact with coagulation factors, thus modulating 
this first step of immune defense [9-11]. Yersinia pestis, for example, suppresses fibrin 
generation via the plasminogen activator Pla thereby reducing recruitment of leukocytes to 
the infection site [12].  
In view of these facts and the frequent occurrence of bleeding abnormalities during C. 
canimorsus infection we investigated the impact of C. canimorsus on hemostasis. We 
demonstrate that the blood culture isolate, C. canimorsus 5 (Cc5), blocks coagulation via the 
bacterial dipeptidyl peptidase CcDPP7, which inactivates coagulation factor X (FX) by 
proteolytic cleavage. We hypothesize that this could contribute to immune evasion of the 
bacteria and to the hemorrhage observed in patients. 
 
 
 
                                                             
* of all cases 
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Methods 
Bacteria and growth conditions 
Bacterial strains are listed in table S5. Cc5 was grown on blood agar plates (heart infusion 
agar (Difco)), 5% defibrinated sheep blood (Oxoid), gentamycin). E. coli strains were 
routinely cultured in LB medium (Invitrogen). Concentrations of antibiotics used: 10 µg/ml 
erythromycin (Em), 10 µg/ml cefoxitin (Cf), 20 µg/ml gentamicin (Gm), 50 µg/ml kanamycin 
(Km) and 100 µg/ml ampicillin (Ap), nalidixic acid (35 µg/ml).  
 
Preparation of NPP 
Human plasma was obtained from 16 healthy volunteers. Blood was withdrawn into 
vacutainer tubes (venosafe, TERUMO) containing 0.109 mol/l buffered sodium citrate and 
centrifuged twice at 2500 x g for 15 min at RT. NPP was snap frozen and stored at -80°C. 
The study was approved by the ethics committee of Mont-Godinne, Belgium (Protocol 
number B039201316262) and performed according to the declaration of Helsinki and the 
Belgian law on experiments in humans from March 7th, 2004. Participants were informed 
about the aim of the study and risks of blood withdrawal and gave written consent. 
 
Calibrated automated thrombogram (CAT) assay 
All bacteria were grown on blood agar, incubated with NPP and cell-free supernatants were 
added to MP- or PPP-Reagent (Thrombinoscope BV). Control NPP was mixed with a 
Thrombin Calibrator (Thrombinoscope BV). Thrombin generation was monitored on a 
Fluoroskan Ascent (Thermo Scientific) after FluCa (Thrombinoscope BV) injection. 
Calculations were performed with the Thrombinoscope software (Thrombinoscope BV). 
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Clotting Time measurements 
PT, aPTT, thrombin and reptilase time were assessed with STA-Neoplastin R (Stago), 
HemosIL SynthASil (Instrumentation Laboratory), STA-Thrombin (Stago) or STA-Reptilase 
(Stago), repectively. 
 
Coagulation factor activity assay 
Activities were determined with deficient plasma (Stago): STA-Immunodef FII (00740), STA-
Deficient FV (00744), STA-Deficient FVII (00734), STA-Immunodef FIX, STA-Deficient FX 
(00738), STA-Deficient FXI (00723), and STA-Immunodef FXII (00315). Standard curve 
measurements were performed according to the manufacturer’s instructions. In brief a series 
of NPP dilutions in Owren-Koller buffer (Stago) was mixed 1:1 with deficient plasma. A 1:10 
dilution was assigned as 100 % factor activity. PT was measured to determine FII, FV, FX 
and FVII activity or the aPTT for FIX, FXI and FXII. Clotting times were plotted against factor 
dilution. Plasma supernatants were diluted 1:10 and mixed 1:1 with factor deficient plasma. 
Clotting was triggered immediately.  
 
Experiments with radiolabeled FX 
Radiolabeling of 50 µg FX (Haematologic Technologies) with Na125I (1 mCi) (Perkin Elmer) 
was performed using pre-coated iodination tube (cat. no.: 28601, Pierce). Iodine 
incorporation constituted 3.7% of total iodine. Bacteria were incubated with 125I-FX in NPP 
for 1h at 37°C. AEBSF (4-(2-aminoethyl)benzenesulfonyl fluoride) treatment was performed 
with 2x109 bacteria/ml at RT. Cell free supernatants were run on a 12 % Nupage Novex Bis-
Tris gel (lifetechnologies) with MOPS buffer (lifetechnologies). The dried gel was exposed to 
a Phosphor Screen (multisensitive, PerkinElmer) which was scanned with a Cyclone 
Phosphor Imager (PerkinElmer).  
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Generation of knock-out mutants 
Primers are listed in table S6. Site directed mutagenesis was performed as described by 
Mally et al. [13] using primers 1.1 and 1.2 to amplify the upstream flanking region (fragment 
1) and primers 2.1 and 2.2 to amplify the downstream flanking region (fragment 2) of the 
gene to be knocked out. Primers 3.1 and 3.2 were used to amplify the ermF resistance 
cassette (fragment 3). In contrast to Mally et al. we first fused fragment 1 with fragment 3 in 
a separate PCR reaction before fusing this to fragment 2.  
Construction of complementation and expression plasmids 
Plasmids and primers are listed in table S7 and S6, respectively. The dpp7 gene was 
amplified with primers 7982 and 7983 and inserted in pMM47 [13] generating the 
complementation plasmid pKH28. Dpp7 was amplified with primers 7982 and 7989 
introducing a C-terminal Strep-His tag, and inserted into pPM5 [14] to generate plasmid 
pKH32. Plasmids were purified from One Shot® TOP10 Electrocomp™ E. coli (Thermo) and 
transformed into Cc5 Δdpp7 bacteria. Positive clones were isolated on cefoxitin blood agar 
plates. Primers 5451 and 4730 or 7809 and 4730 were used for sequencing of inserts in 
pMM47 or pPM5, respectively.  
 
Construction of the catalytic CcDPP7 mutant  
We introduced a point mutation in the dpp7 gene replacing the active site serine residue of 
CcDPP7 by an alanine (S649A) and added a C-terminal Strep-His tag for purification. Dpp7 
was amplified in two fragments using primers 7982 and 7999 or 7998 and 7989, which were 
then fused with primers 7982 and 7989 (Table S6). The product was inserted into pPM5 
generating pKH33. We then proceeded as described above.  
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Protein purification 
Cc5 Δdpp7 (pKH32) and Cc5 Δdpp7 (pKH33) bacteria were disrupted with a French press. 
Cleared lysates were purified with a HisTALON resin (Clontech Laboratories, Inc.) and a 
Streptactin resin (Iba) according to the manufacturers’ instructions. Purity was assessed by 
silver staining as described [15] (Fig. S1). 
 
Immunoblotting 
The following primary antibodies were used: rabbit antiserum raised against purified 
CcDPP7-Strep-His (1:5000, this work), mouse Mab HFX-LC and Mab HFX-HC (1:1000 and 
1:1500 respectively, Enzyme Research Laboratories), rabbit anti-F10A cleaved Ala41 
(1:1000, AssaybioTech). The following secondary antibodies were used: swine anti-rabbit 
HRP (1:5000, Dako), goat anti-mouse HRP (1:5000, Dako). Lumiglo Reserve 
Chemoluminiscent Substrate (KPL) was used for development according to the 
manufacture's instructions. 
 
Quantification of CcDPP7 release  
160 µl of supernatants of NPP or HIP treated with 109 Cc5 wt, Δdpp7 or with PBS were 
added to 40 µl of Met-Leu-AMC (L-Methionyl-L-Leucyl-4-methylcoumaryl-7-amide, 
Peptanova, final concentration of 250 ng/ml) and incubated for 8min at 37°C. Fluorescence 
was read on a Fluoroskan Ascent (excitation/emission 355nm/460nm). A dilution series of a 
CcDPP7 standard was added for quantification purposes. 
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N-terminal sequencing 
25 µg of FX in PBS were incubated with or without CcDPP7 for 30min at 37°C. Concentrated 
samples (Amicon Ultra-0.5 10K MWCO filters, Millipore) were applied to a Nupage Novex 
Bis Tris gel (lifetechnologies). Proteins were transferred on a PVDF membrane (Amersham) 
and visualized with Coomassie R250 brilliant blue. Sequencing was carried out at the 
laboratory for Protein Biochemistry and Biomolecular Engineering at the University of Gent, 
Belgium. 
 
Effect of CcDPP7 on clotting factors 
Purified clotting factors (Haematologic technologies) were incubated with CcDPP7 or 
CcDPP7S649A in PBS. FIX and FX were diluted 1:5 in factor deficient plasma to 5 µg/ml and 
10 µg/ml, respectively. 0.5 µg/ml FVII and 10 µg/ml FII were mixed 1:1 with factor deficient 
plasma.  
 
Evaluation of tail bleeding time 
Balb/c mice were obtained from the University of Namur and Harlan Laboratories 
(Netherlands) and housed at the animal facility of the University of Namur. Experiments were 
performed in accordance with institutional guidelines and its animal bioethics consent 
(approval no. UN LE 13/205). Mice were injected with 200 µl of 1 mg/kg of CcDPP7 or with 
200 µl of the vehicle PBS. Warfarin was administered for 3 days with the drinking water. 
After anaesthesia with ketamin/domitor (82.5 mg/kg / 0.55 mg/kg) a 5 mm long piece of the 
tail tip was removed and the tail was submerged in 37 °C warm PBS. The total bleeding time 
represents all bleeding periods that occurred within 10 min.  
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Results 
Cc5 inhibits thrombin generation 
To determine if C. canimorsus interferes with coagulation we performed a CAT assay, in 
which thrombin generation was monitored with a fluorogenic thrombin substrate. We 
incubated normal pooled plasma (NPP) with different amounts of Cc5 bacteria and induced 
thrombin generation via the intrinsic (MP-Reagent), or the extrinsic pathway (PPP-Reagent) 
at different time points. Both pathways were affected at concentrations from 107 bacteria/ml 
and completely blocked from 108 bacteria/ml. The inhibitory effect already occurred after 
15min (Fig. 1A; Table S1) and increased slightly when the incubation time was prolonged to 
1h (Fig. 1B, Table S2). A slight, but insignificant acceleration of thrombin generation 
occurred with MP-Reagent which might result from the activation of the intrinsic pathway on 
the surface of Cc5 as shown for other bacteria [16]. Two other Gram-negative control 
strains, E. coli MG1655 and Y. enterocolitica E40, did not inhibit thrombin generation and 
paraformaldehyde (PFA) fixed Cc5 only slightly reduced the amount of generated thrombin 
(Fig. 1C, Table S3), suggesting that the inhibitory effect was specific to Cc5 and mediated 
by an active mechanism. 
 
Cc5 prolongs PT and aPTT 
We next measured the prothrombin time (PT) and the activated partial thromboplastin time 
(aPTT) of Cc5 treated NPP, which allow the detection of deficiencies in the extrinsic and the 
common pathway or in the intrinsic and the common pathway, respectively [17, 18]. Since 
this method is less sensitive than the CAT assay, 109 bacteria/ml were used and incubated 
for 1h. NPP treated with Cc5 showed a 10-fold increased PT (Fig. 1D) and a 2- to 3-fold 
increased aPTT (Fig. 1E), thus confirming that Cc5 exerts an inhibitory effect on the 
coagulation cascade and that all pathways are impaired. Testing the activity of different 
coagulation factors, we found that four vitamin K dependent (VKD) clotting factors were 
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affected. FX and FIX activity was strongly decreased to 1 % of normal and FII and FVII 
activity to over 50 %, hinting either towards a dysfunction or a depletion of these factors by 
the bacteria (Table 1A). There was no effect on fibrin(ogen) as confirmed by a thrombin and 
a reptilase time assay both of which allow the detection of fibrin(ogen) deficiencies, (Table 
1B).  
 
FX is cleaved by a bacterial serine protease 
We carried on investigating the fate of FX, one of the most affected VKD factors. Incubating 
Cc5 bacteria with NPP spiked with radiolabeled FX we observed protein modifications, with 
a slight shift of FX heavy chain (HC) and light chain (LC). These no longer occurred upon 
prior treatment of the bacteria with the irreversible serine protease inhibitor AEBSF (Fig. 2A) 
suggesting cleavage by a bacterial serine protease. In addition, there was Cc5 mediated 
generation of two faint bands below the HC, which were still visible after AEBSF treatment of 
the bacteria, indicating that another bacterial factor, potentially another protease, or a 
deglycosylase also affected FX. As pre-incubation of Cc5 with AEBSF completely abolished 
the increased clotting times (Fig. 2B), serine protease mediated FX LC and HC degradation 
seems to be the main cause of the increase of aPTT and PT and will be the focus of this 
paper.  
 
Identification of the bacterial serine protease affecting FX activity 
According to the MEROPS protease database, the Cc5 genome [19] encodes 27 potential 
serine proteases (Table S4) which we individually deleted by gene directed mutagenesis. All 
mutants behaved like wt bacteria (data not shown), except one, ∆Ccan_08540, which no 
longer led to an increased PT (Fig. 3A). There was still a small increase of the aPTT (Fig. 
3B) which might result from the hypothetical second factor modifying FX HC or from an 
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interaction of Cc5 with molecules in the aPTT reagent. The normalization of PT and aPTT in 
∆Ccan_08540 bacteria treated NPP coincided with intact FX function (Fig. 3C) and the 
disappearance of the HC and LC band shift of FX (Fig. 3D). A complemented strain of 
∆Ccan_08540, ∆Ccan_08540 (pKH28), behaved similarly to wt Cc5, meaning that the 
mutation of Ccan_08540 was indeed responsible for the phenotype (Fig. 3A-C). These 
findings indicate that Ccan_08540 encodes a serine protease, which is responsible for FX 
cleavage and inhibition of coagulation.  
 
Ccan_08540 encodes a dipeptidyl peptidase 7 (DPP7) homolog. 
In MEROPS the protein encoded by Ccan_08540 is annotated as a dipeptidyl peptidase 11 
(DPP11) like protease, a member of the S46 family of serine proteases. Aligning the amino 
acid sequence of the Ccan_08540 protease with that of the DPP11 homolog of 
Porphyromonas gingivalis (PgDPP11) [20] (Fig. S2) we found that Ccan_08540 has a 
glycine residue instead of an arginine at P667. Since this arginine is a hallmark of DPP11 
proteases [21], its substitution by a glycine as in PgDPP7, another P. gingivalis dipeptidyl 
peptidase, indicates that Ccan_08540 is rather a member of the DPP7 subgroup of S46 
proteases [21]. We therefore called it CcDPP7. The Ccan_08540 gene, which we named 
dpp7, could be identified in all 26 C. canimorsus strains, that we have sequenced so far, with 
a gene identity of over 99% (Fig. S3A). Cc5 also possesses a DPP11 homolog, which is 
encoded by Ccan_11580, but it is not implicated in the anticoagulant effect (data not shown).  
CcDPP7 homologs are present in the genome of other Capnocytophaga species, such as 
Capnocytophaga cynodegmi and Capnocytophaga canis, that only cause wound infections, 
but no sepsis (Fig. S3A) [1, 22]. 12 further C. canimorsus and 3 C. canis strains, which we 
tested, increased PT and aPTT in a similar manner. 3 tested C. cynodegmi strains were less 
efficient in affecting the PT, but prolonged the aPTT like C. canimorsus (Fig. S3B). 
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CcDPP7 is released into plasma via bacterial lysis 
Being devoid of a signal peptide CcDPP7 is likely to be cytoplasmic. Since the Cc5 genome 
contains no evidence of a machinery allowing active secretion, except for the gliding motility 
system [19], and since C. canimorsus is killed by complement at high plasma concentrations 
[23], we speculated that complement-mediated lysis could induce CcDPP7 release. 
Incubating 109 bacteria/ml in NPP, we observed that 60% of the bacteria had died within 
15min (Fig. 4A). No more killing occurred up to 1h. When complement was inactivated by 
heat treatment of plasma (HIP) there was no killing and even slight growth. Using a 
fluorogenic dipeptide substrate cleaved by CcDPP7, we observed a strong time-dependent 
increase of fluorescence in the supernatants of NPP, but not in HIP incubated with Cc5 wt 
bacteria (Fig. 4B) suggesting the liberation of CcDPP7 by bacterial lysis. In the same 
conditions, ∆dpp7 bacteria led to low fluorescence confirming that substrate cleavage was 
mainly caused by CcDPP7. Using serial dilutions of purified CcDPP7 (Fig. S1) we calculated 
that 109 wt Cc5/ml of NPP release an average 942 ng of CcDPP7 (Fig 4C). This might be 
slightly overestimated given the low activity of other Cc5 proteases on the substrate. 
However, if we assume 60% lysis (Fig. 4A), the value is in the same range as that obtained 
by a quantitative western blot (WB) which showed that 109 bacteria contain on average 1.49 
µg of CcDPP7 (Fig. 4D). To conclude, CcDPP7 is rapidly released into plasma via bacterial 
lysis. 
 
CcDPP7 cleaves the N-terminus of FX LC and HC  
We next characterized the cleavage of FX by purified CcDPP7. We first confirmed the 
anticoagulant action of the purified protease. Indeed NPP incubated with CcDPP7 showed a 
dose dependent increase of PT and aPTT (Fig. 5A), reduced VKD factor activity (Fig. 5B) 
and altered molecular weight of FX (Fig. 5C,D). A catalytic mutant of CcDPP7, CcDPP7S649A, 
where the active serine had been replaced by an alanine, was inactive. To test the efficiency 
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of CcDPP7 in cleaving FX we performed a PT assay with FX deficient plasma, which we 
supplemented with FX that was pre-treated with CcDPP7 at different concentrations. We 
observed a significant increase of the PT starting from an enzyme to substrate ratio of 1:50 
(by weight) compared to the control (Fig. 6A), which corresponds to the ratio needed to 
significantly increase the PT in NPP (Fig. 5A), assuming a plasma FX concentration of 10 
µg/ml. The PT maximum was reached at ratios of 1:10 to 1:4. To exclude any interference of 
CcDPP7 with FX deficient plasma at the moment of induction, we added a control incubating 
FX and CcDPP7 separately and only mixing them upon addition to FX deficient plasma 
when clotting was induced. The PT was normal in this condition meaning that the effect was 
only triggered by the interaction of CcDPP7 with FX. 
We additionally monitored FX degradation by SDS-PAGE followed by silver staining and 
found that a CcDPP7 to FX ratio of 1:1000 was already sufficient to initiate a clearly visible 
band shift of FX HC (Fig. 6B). The LC shift was more obvious from 1:250 indicating that 
CcDPP7 could have a higher specificity for the HC. The discrepancy between this test and 
the PT assay may result from the high sensitivity of the silver staining, which already 
detected partial degradation, and the low sensitivity of the Neoplastin reagent, which 
contains high amounts of TF.  
The DPP7 homolog of P. gingivalis is an aminopeptidase [24]. Exploring whether CcDPP7 
degrades the FX N-terminus we incubated FX with CcDPP7 at different ratios and analyzed 
FX LC by WB using an antibody recognizing the first 20 amino acids (aa). There was 
reduced antibody binding from a 1:250 ratio indicating N-terminal cleavage (Fig. 6C). 
CcDPP7S649A did not induce amino-terminal cleavage of the LC (Fig. S4). N-terminal 
sequencing was performed to confirm the result and to investigate the fate of the HC. Since 
at a ratio of 1:4 no more binding of the LC antibody occurred and the FX HC and LC were 
shifted to a maximum, suggesting that all FX molecules had been cleaved (Fig. 6B), we 
decided to use this condition for sequencing. We found that mainly 10 N-terminal aa of the 
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HC and 2 residues of the LC were missing (Fig. 6D) confirming the aminopeptidase nature 
of CcDPP7.  
Apart from FX, CcDPP7 also acted on FIX (Fig. 5B,S5C) and FVII, but the latter action was 
weaker and less specific (Fig. 5B,S5B). It is likely that the N-termini of FIX and FVII undergo 
limited cleavage, but so far we have no evidence for this. CcDPP7 reduced FII activity in 
NPP (Fig. 5B), but did not reduce the activity of purified FII (Fig. S5A). This raises the 
question whether the impact of CcDPP7 on FII observed in NPP was overestimated due to 
an effect on multiple coagulation factors or if our assay with purified FII was not sensitive 
enough. 
 
CcDPP7 is active in vivo 
In order to confirm the anticoagulant activity of CcDPP7 in vivo we administered the enzyme 
to Balb/c mice by intravenous injection. 1h after CcDPP7 administration the median tail 
bleeding time was 2-fold higher than the control (Fig. 7). Mice of the positive control group, 
which had received warfarin, showed a 3-fold increase in the median tail bleeding time 
compared to the MOCK treated control group.  
 
Discussion 
Although coagulation disorders classically accompany generalized infections, the bleeding 
and coagulation abnormalities are particularly severe in the case of C. canimorsus infection, 
often leading to therapeutic amputations [25-29]. Investigating the possible interaction 
between C. canimorsus and hemostasis we found that Cc5 inhibited coagulation of human 
plasma via a bacterial serine protease of the DPP7 type (CcDPP7) which caused cleavage 
of the N-terminus of FX LC and HC. Removal of all, but three aa of the FX activation peptide 
hampers the activation by the intrinsic Xase [30]. The HC cleaved by CcDPP7 lacks only 10 
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aa, but this could be sufficient to decrease the rate of FX activation. CcDPP7 predominantly 
cleaves 2 aa from the N-terminus of the LC, which comprises a γ-carboxyglutamic acid (Gla) 
domain. Already the absence of the very first alanine (A1) residue can affect FX activity by 
preventing the formation of hydrogen bonds with Gla16, Gla20, Thr21 and Gla21, which 
normally mediate conformational stability of the Gla-domain [31]. In addition, A1 contributes 
to the generation of a Ω-loop, which stretches until glycine 11 [31] and is necessary for the 
interaction of the Gla-domain with membrane surfaces [32]. This suggests that, although 
CcDPP7 only cleaves few residues from the FX HC and LC N-terminus it could be sufficient 
for FX inactivation. 
 
It would be of great interest to identify the mechanism of interaction of CcDPP7 with FX, 
which should help to clarify its preference for certain factors, and to investigate why CcDPP7 
stops cleaving after a limited number of aa from HC and LC. Even with very high enzyme 
concentrations no further cleavage occurs (Fig. 6B). A possible cause could be 
posttranslational modifications presenting steric hindrance, such as glycans or a complex 
secondary structure making further aa residues less accessible. 
 
Due to its intracellular location CcDPP7 might essentially be a housekeeping protease, 
which could nevertheless play a role in cleaving clotting factors in plasma, because it is 
strongly released by the complement mediated lysis of Cc5 bacteria. Since CcDPP7 is also 
expressed by strains not causing invasive infections it is clear that the possession of 
CcDPP7 alone does not suffice to make C. canimorsus a pathogenic bacterium. Other 
factors, such as the weakly endotoxic LPS [33], the resistance to phagocytosis [34], the 
capacity to capture iron [14] and the N-glycoproteins deglycosylation [35] cooperate to 
determine pathogenicity. Unfortunately the investigation of virulence factors has been 
hampered by the lack of animal model permitting to investigate the pathogenesis in vivo. 
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Rabbits [36], mice and hamsters (unpublished data) clear bacteria completely. In vitro, using 
human plasma, CcDPP7 was effective in the nanogram range and 107 bacteria/ml sufficed 
to affect thrombin generation. In the mouse, approx. 17 µg of pure CcDPP7/ml blood were 
required to increase the tail bleeding time. We have no obvious explanation for this 
discrepancy, but protein stability, the presence of inhibitors or other unknown targets in 
murine blood could play a role.  
 
Some clinical reports mention the presence of extracellular bacteria in peripheral blood 
smears [37, 38] indicating a high bacterial load. However, in most cases, C. canimorsus was 
only detected by culture suggesting lower bacterial numbers. This raises the question 
whether CcDPP7 could have a systemic activity. 
A generalized anticoagulant effect would probably only occur at advanced stages of sepsis 
when bacteremia is high and many bacteria have lysed releasing their intracellular content. 
CcDPP7 levels are probably not sufficient to prevent DIC, there could be at most 
aggravation of DIC induced hemorrhage.  
C. canimorsus adheres to various cell types including endothelial cells (unpublished data) 
and vegetations have been found within the heart [39]. A local inhibition of coagulation by 
agglomerates of adhering bacteria in tissues, organs or blood vessels releasing CcDPP7 
seems to be more probable. Brenner et al. mention a C. canimorsus isolate derived from a 
petechial lesion [1] pointing to the presence of C. canimorsus in the skin, which is interesting 
with respect to the skin hemorrhage observed in patients. It is tempting to speculate that C. 
canimorsus could directly induce skin manifestations like Neisseria meningitidis [40, 41] or 
that it could reduce the inflammatory response and clearance like Y. pestis [12] by locally 
blocking hemostasis. 
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To conclude, we demonstrate a novel mechanism for the inactivation of FX by a DPP7 type 
protease. This effect on FX could contribute to local inhibition of coagulation or maybe to an 
aggravation of DIC induced bleeding. It could equally be a mechanism by which C. 
canimorsus evades detection and killing by the immune system.  
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Tables 
Table 1. (A) Activity of selected coagulation factors and (B) thrombin and reptilase times of 
NPP incubated for 1h at 37°C with 109 Cc5 bacteria/ml or PBS as control. 
 
  
A 
 
Factor activities [%]1 ± SD 
  
NPP + PBS NPP + Cc5
 
 FII 92 ± 7 44 ± 4 (p=0.0006)2 
 FV 95 ± 17 96 ± 14 
 FVII 100 ± 4 45 ± 1 (p<0.0001) 
 FIX 105 ± 0 1 ± 0 (p<0.0001) 
 FX 81 ± 6 1 ± 0 (p<0.0001) 
 FXI 64 ± 5 71 ± 6 
 FXII 98 ± 13 122 ± 17 
      
B 
 
Clotting Times [s] 
  
NPP + PBS NPP + Cc5 
 Thrombin time 17.3 ± 0.1 20.1 ± 1.8 
 Reptilase time 17.5 ± 0.5 18.3 ± 1.2 
      
1
 Factor activities were determined with factor deficient plasma. Sample plasma was 
diluted 1:10 in Owren Koller buffer, mixed 1:1 with factor deficient plasma and PT (FII, 
FV, FVII, FX) or aPTT (FIX, FXI, FXII) were measured. The activity was calculated by 
means of a standard curve which was obtained by mixing different dilutions of a 
calibrator NPP, starting from 1:10, with equal volumes of the appropriate factor 
deficient plasma. The 1:10 dilution of standard NPP was arbitrarily assigned to a 
factor activity of 100%. 
2 For statistical analysis One-way ANOVA followed by a Bonferroni test was carried 
out. P-values represent statistical significance compared to the control (NPP + PBS) 
SD = standard deviation, NPP = normal pooled plasma, PBS = phosphate buffered 
saline 
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Figure Legends 
Figure 1. Cc5 inhibits thrombin generation and leads to increased clotting times. 
Thrombin generation profiles of NPP after incubation with different concentrations of Cc5 for 
15 min (A) and 1 h (B). PBS only (ctrl) or bacterial suspensions in PBS were diluted 1:10 in 
NPP to make the final dilutions of 106 - 109 Cc5 bacteria/ml and incubated at 37 °C. (C) 
Thrombin generation profiles of NPP after incubation for 15 min at 37 °C with PBS (ctrl) or E. 
coli MG1655, Y. enterocolitica E40, live Cc5, PFA fixed Cc5, all at 109/ml. Thrombin 
generation was monitored with a Fluoroskan Ascent after addition of MP-Reagent (4 μM 
Phospholipids) or PPP-Reagent (5 pM TF, 4 μM Phospholipids) and FluCa (fluorogenic 
thrombin substrate + CaCl2). Shown are representative results from three independent 
experiments performed in triplicate. (D, E) Cc5 bacteria (109/ml) or PBS (ctrl) were incubated 
at 37°C with NPP for 1 h. For PT measurements coagulation was induced with STA-
Neoplastin R (D), for aPTT measurements with HemosIL SynthASil (E). Shown are average 
clotting times of at least three independent experiments performed in duplicate. Error bars 
represent the standard deviation. ***, P≤0.001 compared to control determined with a 
Student’s t-test. 
 
Figure 2. A serine protease mediates FX cleavage and causes increased clotting 
times. (A) Autoradiography of I125-FX. 3 µg/ml iodinated FX were added to NPP and 
incubated either with PBS (ctrl) or wt bacteria in PBS pre-incubated for 30 min in the 
presence or absence of 1 mM AEBSF. The dashed line helps to visualize the size shift. 
Shown is a representative image of three independent experiments. (B) PT and aPTT 
measurements of NPP treated with Cc5 wt bacteria in PBS pre-incubated for 30min in the 
presence or absence of 1 mM AEBSF. For the control (ctrl) either PBS or 1 mM AEBSF in 
PBS were added to NPP. Shown are mean values (±SD) of three independent experiments 
each performed in triplicate (ns, not significant; ***, p≤0.001 compared to control). 109 
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bacteria/ml were used for all conditions, the incubation was always performed for 1h at 37 
°C. One-way-ANOVA with a Bonferroni post-test was used for statistical analysis. 
 
Figure 3. Deletion of the gene Ccan_08540 restores normal PT and aPTT values, FX 
function and FX protein integrity. Complementation of ∆ Ccan_08540 with the 
Ccan_08540 expression plasmid pKH28 leads again to increased clotting times and 
impaired FX activity. (A, B) PT and aPTT values of NPP incubated with PBS (ctrl) or 109 
bacteria/ml of Cc5 wt, ∆Ccan_08540 (∆08540) or the complemented strain ∆Ccan_08540 
(pKH28) (∆08540 (pKH28)). Shown are mean values (±SD) of at least four independent 
experiments each performed in duplicate. (C) FX activity of NPP incubated in the absence or 
presence of 109 bacteria/ml was measured with factor deficient plasma. Shown are mean 
values (±SD) of three independent experiments each done in duplicate. Statistical analysis 
was performed comparing with the control (***, p≤0.001). (D) Representative 
autoradiography of I125-FX in NPP incubated with PBS (ctrl) or 109 bacteria/ml. The dashed 
line helps to visualize the size shift. All experiments were performed for 1 h at 37 °C. One-
way-ANOVA with a Bonferroni post-test was used for statistical analysis. 
 
Figure 4. CcDPP7 release into NPP is mediated by lysis of Cc5. (A) Cc5 is killed in NPP. 
109 Cc5 wt bacteria/ml were incubated for the indicated time points with NPP or HIP and cfu 
counts were quantified by plating. Shown is the percentage of surviving/growing bacteria 
relative to the inoculum. ***, p≤0.001 (B) CcDPP7 release into plasma is triggered by 
bacterial lysis. 109 bacteria/ml of Cc5 wt or ∆dpp7 were incubated with NPP or HIP for the 
indicated time-points. PBS only was used as control. CcDPP7 release was monitored using 
a fluorogenic Met-Leu-AMC substrate. Depicted is the average fluorescence (±SD) of 3 
independent experiments. ***, p≤0.001; ns, not significant versus NPP/HIP incubated with 
∆dpp7 bacteria. (C) The average CcDPP7 concentration (±SD) in NPP and HIP was 
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calculated based on the fluorescence generated in each of the 3 experiments using purified 
CcDPP7 as a standard. (D) Quantification of CcDPP7 expression by Cc5. Shown is an anti-
CcDPP7 western blot. 10 µl of purified CcDPP7 or Cc5 wt bacteria at the indicated 
concentrations in sample buffer were loaded onto an SDS-PAGE gel. Shown is a 
representative blot and standard curve of 3 independent experiments as well as the average 
CcDPP7 amount (±SD) expressed by 109 Cc5 wt bacteria. The band intensities were 
quantified with the Amersham Imager 600 software and the average amount of CcDPP7 
expressed by 109 Cc5 wt bacteria was calculated from 3 independent experiments. 
 
Figure 5. (A, B) NPP treated with purified CcDPP7 shows prolonged PT and aPTT and 
reduced VKD factor activity. (A) CcDPP7, CcDPP7S649A or PBS were diluted 1:10 in NPP to 
the indicated concentrations, incubated at 37 °C for 1 h and PT and  aPTT were measured. 
One-way ANOVA with a Bonferroni post-test was performed for statistical analysis 
comparing to the untreated control, *** p≤0.001. (B) The activity of FII, FVII, FIX and FX in 
NPP treated for 1h at 37°C with PBS, 200 ng/ml of CcDPP7 or CcDPP7S649A were measured 
with factor deficient plasma. Shown are the results of three independent experiments (±SD) 
each done in duplicate. For statistical analysis one-way ANOVA with a Bonferroni post-test 
was performed comparing to NPP + PBS. (C, D) CcDPP7 causes FX LC and HC cleavage 
in NPP. Shown are cropped images of anti-FX LC (C) or HC (D) western blots of NPP 
incubated for 1h at 37°C in the presence or absence of 200 ng/ml of CcDPP7 or 
CcDPP7S649A. 10 µl of plasma samples diluted 1:20 were loaded. 10 µl of 1:20 diluted FX 
deficient plasma served as negative control. Dashed lines were drawn to visualize the band 
shift. Shown is a representative result of 3 independent experiments.  
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Figure 6. FX is degraded by N-terminal cleavage. (A) CcDPP7 affects FX function in a 
dose dependent manner. 50 µg/ml of FX were incubated for 30min at 37°C in the presence 
or absence of CcDPP7 or CcDPP7S649A at the indicated enzyme to substrate ratios (by 
weight) and subsequently added to FX deficient plasma at a concentration of 10 µg/ml. To 
exclude any interaction of CcDPP7 with FX deficient plasma at the moment of induction, a 
control was included for which FX and CcDPP7 were first incubated separately and only 
mixed upon addition to FX deficient plasma when the inducer was added (n.c. = no 
coincubation). Shown are mean values and standard deviations of three independent 
experiments each performed in triplicate. ***, p≤0.001 versus control. One-way-ANOVA with 
a Bonferroni post-test was used for statistical analysis. (B) Degradation of pure human FX by 
CcDPP7 happens in a dose dependent manner, but reaches a limit at high doses. 50 µg/ml 
of FX in PBS were incubated with CcDPP7 at the indicated ratios (by weight) for 30min at 
37°C. 10 µl of each sample in sample buffer were loaded. Shown is a representative silver 
staining of 3 independent experiments. (C, D) FX is degraded by CcDPP7 via N-terminal 
cleavage. (C) Western blot for amino acids 1-20 of FX LC. 50 µg/ml of purified human FX in 
PBS were incubated with the indicated concentrations of CcDPP7 or CcDPP7S649A for 30min 
at 37°C. 10 µl of each sample in sample buffer were loaded. Shown are representative 
results of three independent experiments. (D) 50 µg/ml of purified human FX in PBS was 
incubated in the presence or absence of 12.5 µg/ml of CcDPP7. Automated N-terminal 
Edman degradation was performed on LC and HC. Amino acid sequences from two 
independent experiments are shown. Sequences in bold were the most highly abundant in 
both experiments.  
 
Figure 7. CcDPP7 prolongs the bleeding time in vivo. 1 mg/kg CcDPP7 or PBS as 
control were injected into the tail vein of male Balb/c mice. Bleeding times were measured 1 
h after injection. The positive control group received 5 mg/l of warfarin in the drinking water 
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for 3 days. *, p≤0.05; ***, p≤0.001 versus vehicle treated control. One-way-ANOVA with a 
Bonferroni post-test was used for statistical analysis. 
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